RS51195B - Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema - Google Patents

Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema

Info

Publication number
RS51195B
RS51195B RSP-2009/0437A RSP20090437A RS51195B RS 51195 B RS51195 B RS 51195B RS P20090437 A RSP20090437 A RS P20090437A RS 51195 B RS51195 B RS 51195B
Authority
RS
Serbia
Prior art keywords
epa
drug
use according
ethyl ester
dha
Prior art date
Application number
RSP-2009/0437A
Other languages
English (en)
Serbian (sr)
Inventor
Tiberio Bruzzese
Original Assignee
Tiberio Bruzzese
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34803698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS51195(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tiberio Bruzzese filed Critical Tiberio Bruzzese
Publication of RS51195B publication Critical patent/RS51195B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RSP-2009/0437A 2004-01-21 2005-01-20 Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema RS51195B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000069A ITMI20040069A1 (it) 2004-01-21 2004-01-21 Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
PCT/EP2005/000522 WO2005070411A1 (en) 2004-01-21 2005-01-20 USE OF HIGHLY CONCENTRATED COMPOSITIONS OF SELECTED n-3 FATTY ACIDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISTURBANCES

Publications (1)

Publication Number Publication Date
RS51195B true RS51195B (sr) 2010-10-31

Family

ID=34803698

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0437A RS51195B (sr) 2004-01-21 2005-01-20 Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema

Country Status (12)

Country Link
US (1) US8829048B2 (enExample)
EP (1) EP1706106B9 (enExample)
JP (1) JP5087280B2 (enExample)
DE (1) DE602005015415D1 (enExample)
DK (1) DK1706106T3 (enExample)
ES (1) ES2329809T3 (enExample)
HR (1) HRP20090550T1 (enExample)
IT (1) ITMI20040069A1 (enExample)
PL (1) PL1706106T3 (enExample)
PT (1) PT1706106E (enExample)
RS (1) RS51195B (enExample)
WO (1) WO2005070411A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
EP1772146A1 (en) * 2005-10-03 2007-04-11 Neuropharma, S.A. Polyunsaturated fatty acids as bace inhibitors
US7652068B2 (en) 2005-12-20 2010-01-26 Cenestra Llc Omega 3 fatty acid formulations
KR101256448B1 (ko) 2005-12-21 2013-04-19 브루디 테크놀로지 에스엘 세포의 산화적 손상과 연관된 병리상태를 치료하기 위한ｄｈａ, ｅｐａ 또는 ｄｈａ 유래의 ｅｐａ의 용도
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
FI2144618T4 (fi) 2007-03-28 2025-02-13 Aker Biomarine Antarctic As Biovaikuttavat krilliöljykoostumukset
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2008361645A1 (en) 2008-09-09 2010-03-18 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
NZ735362A (en) 2015-02-11 2019-01-25 Aker Biomarine Antarctic As Lipid compositions
PL3256003T5 (pl) 2015-02-11 2025-11-17 Aker Biomarine Human Ingredients As Sposoby ekstrakcji lipidów
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
PL238670B1 (pl) * 2018-07-06 2021-09-20 Skotan Spolka Akcyjna Sposób otrzymywania oczyszczonej kompozycji estrów kwasów tłuszczowych i kompozycja estrów kwasów tłuszczowych
JPWO2022050355A1 (enExample) * 2020-09-04 2022-03-10

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
IT1205043B (it) * 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
DE3739700A1 (de) 1987-11-24 1989-06-08 Guenther Dr Med Jeschke Alpha-linolensaeure (18:3,omega 3) und/oder deren derivate enthaltende formulierungen, sowie verfahren zu ihrer herstellung und anwendung in ernaehrung und medizin
JP2524217B2 (ja) 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
GB2218904A (en) 1988-05-27 1989-11-29 Renafield Limited Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FR2688145B1 (fr) 1992-03-06 1994-09-23 Borden France Sa Procede et installation pour separer un effluent sous forme de vapeur d'un courant de gaz vecteur.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
IT1274734B (it) * 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
PL190181B1 (pl) * 1996-10-11 2005-11-30 Scarista Ltd Zastosowanie oleju zawierającego kwas eikozapentaenowy (KEP) i/lub kwas stearydonowy (KS) oraz preparat farmaceutyczny zawierający olej
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
ATE305810T1 (de) 2000-05-22 2005-10-15 Pro Aparts Investimentos E Con Fettsäure enthaltende pharmazeutische zusammensetzung die wenigstens 80 gew. epa und dha enthält
IT1320180B1 (it) 2000-12-29 2003-11-26 Hunza Di Marazzita Maria Carme Preparazioni nutrizionali e terapeutiche dotate di attivita'antiossidante ed in grado di controllare gli eccessi ponderali e
US6759435B1 (en) * 2003-07-03 2004-07-06 A.P. Group Inc. Antidepressant drugs and methods

Also Published As

Publication number Publication date
EP1706106B1 (en) 2009-07-15
US20070161705A1 (en) 2007-07-12
DE602005015415D1 (de) 2009-08-27
EP1706106A1 (en) 2006-10-04
HRP20090550T1 (hr) 2010-01-31
EP1706106B9 (en) 2009-09-16
ES2329809T3 (es) 2009-12-01
JP2007518764A (ja) 2007-07-12
PT1706106E (pt) 2009-09-04
US8829048B2 (en) 2014-09-09
PL1706106T3 (pl) 2009-12-31
DK1706106T3 (da) 2009-10-12
JP5087280B2 (ja) 2012-12-05
WO2005070411A1 (en) 2005-08-04
ITMI20040069A1 (it) 2004-04-21

Similar Documents

Publication Publication Date Title
RS51195B (sr) Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema
RU2260423C2 (ru) Этил-эпк с высокой степенью чистоты и другие производные эпк для психиатрических и неврологических расстройств
JPH0249723A (ja) 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JP2018104477A (ja) 認知機能改善および心拍数低下のための方法
US20110244052A1 (en) Polyunsaturated fatty acids for improving vision
RS54201B1 (sr) Postupak za pripremu bifenil-2-ilkarbaminske kiseline
WO2015005443A1 (ja) 内服組成物
KR20000035924A (ko) 디스프랙시아의 치료용 약물 조제를 위한 아라키돈산 및/또는 도코사헥사논산의 용도
JPH0672868A (ja) 抗精神病薬
CN106163562A (zh) 在老年人中减少白质病变、白质高信号（wmh）、白质疏松症或室周白质疾病的方法
EP3461479B1 (en) Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions
JP2003535134A (ja) 痴呆治療剤
ITMI20090284A1 (it) Uso di inibitori della serina palmitoiltrasferasi per la prevenzione e il rallentamento delle degenerazioni retiniche ereditarie e relative composizioni
JP7608707B2 (ja) 近視進行抑制剤、機能性食品及び眼科用組成物
US20140343143A1 (en) Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances
JPWO2005046668A1 (ja) 言語障害予防・治療剤
JPH09132553A (ja) ドーパミンまたはＬ−ドーパのｎ−３系不飽和脂肪酸誘導体
AU2004235641B2 (en) Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
RS66464B1 (sr) N-palmitoiletanolamid i dokozaheksaenska kiselina za upotrebu u lečenju poremećaja autističnog spektra i drugih depresivnih sindroma
NZ239126A (en) The use of essential fatty acids to treat schizophrenia and associated tardive dyskinesia
AU2006201772A1 (en) Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders